34 results
Thumbnail

D1.50 - Allergic Bronchopulmonary Aspergillosis in a Tertiary Allergy Center: Clinical Characteristics, Radiologic Subtypes, and Biologic Use

Thumbnail

D1.54 - Latex-Induced Occupational Asthma: An Underrecognized Hazard in the Electronics and Cable Industry

Thumbnail

D1.46 - Molecular patterns of fungal sensitization in patients with asthma and allergic rhinitis: evidence from real-life clinical practice

Thumbnail

D1.47 - Assessment of Asthma Control in Elderly Patients Using Forced Oscillation Technique, Spirometry, and Asthma Control Test in Relation to GINA Classification

Thumbnail

D1.48 - Early-Onset Multiorgan Allergic Phenotype with Transformation into Controlled Asthma in a 2-Year-Old Child: The Role of Molecular Diagnostics (ALEX²) in Risk Stratification

Thumbnail

D1.49 - Component-Resolved Pet Allergen Sensitization Identifies Adolescents With Airway Inflammation and Bronchial Hyperresponsiveness

Thumbnail

D1.51 - Evaluation of the Correlation Between Skin Prick Test, Specific Immunoglobulin E Levels and Clinical Findings in Children with Cat Allergen Sensitization

Thumbnail

D1.52 - The Borg Fallacy in Olympic Athletes: Symptom Perception Fails to Identify Airway Hyperresponsiveness

Thumbnail

D1.55 - Monosensitization to Der p 23 in house dust mite allergy in daily clinical practice in a county of Gipuzkoa, Basque Country, Spain: a retrospective and descriptive analysis

Thumbnail

D1.57 - New allergens registered in the WHO/IUIS Allergen Database in 2025: new and old foes

Thumbnail

D1.58 - “Evaluation of Chronic Cough in Patients with Allergic Disease, GERD, and Chronic Rhinosinusitis”

Thumbnail

D1.60 - Clinical Characteristics of Children with Patch Test–Positive Allergic Contact Dermatitis: Effects of Treatment on Quality of Life

Thumbnail

D1.105 - Real-Life Evidence of Type 2 Immunomodulation with Benralizumab: From Steroid-Dependent to Controlled Asthma

Thumbnail

D1.106 - Dupilumab-Induced Systemic Eosinophilic Immune Activation Mimicking an EGPA-Like Prodrome: A Case Report

Thumbnail

D1.108 - Optimization of phenotyping in severe T2-bronchial asthma

Thumbnail

D1.109 - Biologics selection algorithm for severe T2-bronchial asthma targeted therapy

Thumbnail

D1.110 - Long Term Mepolizumab in Type-2 CRSwNP: Marked Polyp Reduction, Symptom Relief, and Airway Benefits in Real World Comorbid Patients

Thumbnail

D1.111 - Tezepelumab reduces in patients with severe allergic asthma and rhinoconjunctivitis not only bronchial but also nasal and conjunctival symptoms – results from an exposure chamber study

Thumbnail

D1.112 - ILC2 Expansion as a Biomarker of Suboptimal Response to Dupilumab in Severe Asthma: Findings from the PRISM Study

Thumbnail

D1.113 - Effect of mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a real-world retrospective observational study